Project Details


The National Institute on Drug Abuse (NIDA), Medications Development
Division (MDD) has established a Cocaine Treatment Discovery Program
(CTDP) to identify potential treatments for the medical management of
cocaine dependence. This program involves testing compounds through a
decision-based screening scheme which consists of a number of in vitro
and in vivo assays and which is designed to identify potential treatment
agents which either substitute for cocaine or antagonize the effects of

The purpose of this contract is to preclinically evaluate the effects of
100 test compounds on the subjective effects of cocaine; as assessed by
the rat drug discrimination procedure. Depending upon results obtained
from the locomotor activity test, which is conducted under a separate
contract, the test compound will be evaluated for the ability to
substitute for, or antagonize, the discriminative effects of cocaine.

The compounds to be tested under this contract will be selected and, for
the most part, supplied by NIDA. Compounds will be supplied under an
identification code number with appropriate information including
physical properties, solubilities, and recommended starting doses, if
available. CTDP data generated from this contract on proprietary
compounds will be maintained in confidence by NIDA unless permission to
release the data is granted to NIDA by the compound submitter. Compound
submitters are free to disclose CTDP data generated on their compounds
at any time.
Effective start/end date30/09/9529/03/96